JNJ-42226314

JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain[1].

Product Specifications

CAS Number

[1252765-13-1]

UNSPSC

12352005

Target

MAGL

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/jnj-42226314.html

Purity

99.42

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2CN(C(C3=CC4=C(N(C5=CC=C(F)C=C5)C=C4)C=C3)=O)C2)CC1)C6=NC=CS6

Molecular Formula

C26H24FN5O2S

Molecular Weight

489.56

References & Citations

[1]Wyatt RM, et al.Pharmacologic characterization of JNJ-42226314, [1- (4-fluorophenyl) indol-5-yl]-[3-[4- (thiazole-2-carbonyl) piperazin-1-yl]azetidin-1-yl]methanone, a reversible, selective and potent monoacylglycerol lipase inhibitor.J Pharmacol Exp Ther. 2019 Dec 9.